A team of researchers from UCLA and the University of Toronto have identified a new biomarker found in urine that can help detect aggressive prostate cancer, potentially saving hundreds of thousands of men each year from undergoing unnecessary surgeries and radiotherapy treatments.
Homologous recombination deficiency tests are used routinely in the clinic to determine which patients get PARP inhibitors.
